Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 125

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 125
---
 of patents derived from WO 2011/07399, which was filed December 16, 2010. Patents from this family
are nominally due to expire in December 2030 and include patents Nos. US 8,846,020, EP 2513294, CN 102762715 and IL 220343, which are
detailed in the table below.

Family #2 derived from WO 2008/126092
that was filed April 16, 2008 claims conjugates of the serum protein albumin with PEG. This patent may be useful to supplement the protection
of GelrinC which may contain albumin as well as fibrinogen. The family of patent applications derived from WO 2008/126092 includes patents
Nos. US 9,624,259 and EP 2497505, which are detailed in the table below.

Family 

# 4 derived from WO 2014/207749
filed June 24, 2014 claims an injectable curable paste that can be shaped to fill defects requiring treatment. The family of patent applications
derived from WO 2014/207749 includes patents Nos. US 10,434,215, EP 3013377 and CN 105407933, which are detailed in the table below.

Family #6 derived from WO 2015/052708
filed on January 24, 2014 claim an apparatus for treatment of cavities in a human body. The family of patent applications derived from
WO 2015/052708 includes patents Nos. US 9,895,519, US 9,872,705, EP 2874546, CN 106232023 and IL 235270, which are detailed in the table
below.

The patent portfolio of the
Company includes granted patents that cover the products currently in development and additional families of patents that may provide
supplementary protection for those products and further products.

<div align='center'>76</div>

Patents

As of February 10, 2025,
our exclusively owned patent portfolio includes thirty-four (34) issued patents, of which eight (8) are U.S. patents and twenty-six (26)
are foreign patents, with eighteen (18) of the twenty-six (26) foreign patents being nationally validated in certain European extension/validation
states). In addition, one U.S. patent application and two patent applications are pending. The claims of the